A genetic cell context-dependent role for ZEB1 in lung cancer

Ting Zhang(Mayo Clinic), Lixia Guo(Mayo Clinic), Chad J. Creighton(Baylor College of Medicine), Qiang Lü(Mayo Clinic), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Eunhee S. Yi(Mayo Clinic), Bo Deng(Mayo Clinic), Julian R. Molina(Mayo Clinic), Zhifu Sun(Mayo Clinic), Ping Yang(Mayo Clinic), Yanan Yang(Mayo Clinic)
Nature Communications
July 26, 2016
Cited by 71Open Access
Full Text

Abstract

The Zinc-finger E-box-binding Homeobox-1 (ZEB1) is a transcription factor that promotes epithelial-mesenchymal transition (EMT) and acts as an oncogene in KRAS-mutated lung cancer models. Here we report that ZEB1 exerts the opposite effect in EGFR-mutated lung cancer cells, where it suppresses growth by increasing microRNA-200 targets to antagonize ERBB3, a driver of mutant EGFR-dependent cell growth. Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3. Furthermore, we find that EGFR inhibitor treatment, which inhibits the growth of EGFR-mutated cells, induces ZEB1. Despite its growth-inhibiting effect, EGFR inhibitor-induced ZEB1 strongly promotes EMT-dependent resistance to EGFR inhibitors partially through NOTCH1, suggesting a multifunctional role for NOTCH1 in EGFR-mutated cells. These results support a previously unrecognized genetic cell context-dependent role for ZEB1 and suggest that NOTCH1 may be a useful target for treating resistance to EGFR inhibitors, especially EMT-driven resistance.


Related Papers

No related papers found

Powered by citation graph analysis